Original Article

Comparative Expression Profile of Orphan Receptor Tyrosine Kinase *ROR1* in Iranian Patients with Lymphoid and Myeloid Leukemias

Mahdi Shabani [1], Hossein Asgarian-Omran [1], Mohammad Hojjat Farsangi [1], Parvaneh Vossough [2], Ramazan A. Sharifian [3], Gholam R. Toughe [3], Seyed Mohsen Razavi [4], Jalal Khoshnoodi [1], Mahmood Jeddi-Tehrani [5], Hodjatallah Rabbani [5, 6], and Fazel Shokri [1, 5*]

1. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2. Clinic of Hematology, Ali-Asghar Hospital, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
3. Clinic of Hematology and Oncology, Vali-Asr Hospital, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
4. Clinic of Hematology and Oncology, Firozgar Hospital, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
5. Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
6. Immune and Gene Therapy Lab, Cancer Center Karolinska, Karolinska Hospital, Karolinska Institutet, Stockholm, Sweden

Abstract

It has recently been shown that *ROR1*, a member of the receptor tyrosine kinase family, is overexpressed in leukemic B cells of Chronic Lymphocytic Leukemia (CLL) and a subset of Acute Lymphoblastic Leukemia (ALL). In this comparative study the expression profile of *ROR1* mRNA was investigated in Iranian patients with CLL and Acute Myelogenous Leukemia (AML) and the results were compared with those previously reported in our Iranian ALL patients. RT-PCR was performed on bone marrow and/or peripheral blood samples of 84 CLL and 12 AML patients. CLL samples were classified into immunoglobulin heavy chain variable region (IGHV) gene mutated (n=55) and unmutated (n=29) and also indolent (n=42) and progressive (n=39) subtypes. ROR1 expression was identified in 94% of our CLL patients, but none of the AML patients expressed ROR1. No significant differences were observed between different CLL subtypes for *ROR1* expression. Taken together the present data and our previous results on ROR1 expression in ALL, our findings propose *ROR1* as a tumor-associated antigen overexpressed in a large proportion of lymphoid (CLL and ALL), but not myeloid (AML) leukemias. Expression of *ROR1* seems to be associated to lineage and differentiation stages of leukemic cells with a potential implication for immunotherapy.

Avicenna J Med Biotech 2011; 3(3): 119-125

Keywords: Acute myelogenous leukemia, Chronic lymphocytic leukemia, *ROR1*, RT-PCR

*** Corresponding author:**
Fazel Shokri, Ph.D., School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
Tel: +98 21 88953021
Fax: +98 21 66462267
E-mail: fshokri@sina.tums.ac.ir
Received: 13 Jun 2011
Accepted: 2 Jul 2011

Downloaded from http://www.ajmb.org

Introduction

ROR1 is a member of the family of tyrosine kinase receptors which is highly conserved among various species [(1)]. Gene knockout studies in mice have shown the critical developmental role of *ROR1* in heart and skeletal organogenesis [(2)]. Functional *ROR1* ligands have remained unknown, though secreted proteins of the wingless-type MMTV integration site (Wnt) family have recently been proposed as ligand candidates [(3,4)] and Wnt5a was

Copyright © 2011, Avicenna Journal of Medical Biotechnology. All rights reserved.

shown to bind Ror1 [5]. Ten years after identification of *ROR1* [1], gene expression profiling of B cell malignancies on a genomic scale displayed *ROR1* overexpression in leukemic B cells of Chronic Lymphocytic Leukemia (CLL) [6,7].

CLL represents a heterogeneous disease with a highly variable prognosis characterized by the gradual accumulation of small mature $CD19^+/CD5^+/ CD23^+$ B cells [8]. It has a very variable clinical course, with survival ranging from months to decades [9]. The mutational status of the immunoglobulin heavy chain variable region (IGHV) genes categorizes the disease into indolent non-progressive and progressive entities which has been confirmed as an important prognostic marker in prospective clinical trials [10]. Leukemic CLL cells from patients with indolent clinical course typically express mutated IGHV, whereas patients with aggressive clinical course typically express unmutated IGHV [11,12].

Recently, two studies have separately demonstrated that Ror1 protein is uniformly expressed in all CLL samples independent of molecular and clinical heterogeneity or mutational status, whereas normal B cells, other normal blood cells, and normal adult tissues do not express cell surface Ror1 [11,13]. Furthermore, the expression of ROR1 gene has recently been reported in both tumor tissues and Peripheral Blood Mononuclear Cells (PBMCs) of renal cancer patients [14] and non-Hodgkin lymphomas [15,16].

Our recent investigation in a group of Iranian patients with Acute Lymphoblastic Leukemia (ALL) demonstrated *ROR1* overexpression in about 40% of patients [17]. Little is known about the expression pattern of *ROR1* in myeloid leukemias and in Iranian patients with CLL. In the present study we investigated *ROR1* expression in Iranian patients with CLL and Acute Myelogenous Leukemia (AML) and compared the results with our previous findings in Iranian patients with ALL.

Materials and Methods

Patients and controls

Heparinized Bone Marrow (BM) and/or Peripheral Blood (PB) samples were obtained from 84 CLL (only PB) and 12 AML (7 paired BM and PB, 4 BM, and one PB) Iranian patients attending the Hematology and Oncology Clinics of the Vali-Asr hospital affiliated to Tehran University of Medical Sciences and the Oncology Clinics of Firozgar and Ali-Asghar hospitals, affiliated to Iran University of Medical Sciences. A consent letter was taken from all patients or their parents and the study was approved by the Ethical Committee of Tehran University of Medical Sciences. Heparinized PB samples collected from 33 normal healthy donors (13 children with a mean age of 7.1 years and 20 adults with a mean age of 42.7 years) served as controls to determine baseline ROR1 expression and cut-off value.

Nucleotide sequence analysis of the IGHV genes of the leukemic cells has allowed classification of the CLL patients into mutated (n=55) and unmutated (n=29) groups, based on the presence of more than 2% somatic mutation compared to the germline sequence [18]. The patients were clinically classified into indolent (n=42) and progressive (n=39) subtypes [19]. Diagnosis of AML was based on cytomorphological findings (FAB criteria) and immunophenotypic characteristics of BM leukemic cells [20]. Major demographic features of CLL and AML patients have been published [19, 20].

ROR1 PCR

PBMCs of all subjects were isolated by density-gradient centrifugation using Histopaque (Sigma, St. Louis, MO). RNA extraction and cDNA synthesis were performed as previously described [21]. PCR amplification was performed using *ROR1*-specific primers: 5'-CTG CTG CCC AAG AAA CAG AG-3' as sense and 5'-CAT AGT GAA GGA AGC TGT GAT CT-3' as antisense (Gen Bank accession No. NM 005012) and β-actin-specific primers: 5'-ATG GCC ACG GCT GCT TCC

Downloaded from http://www.ajmb.org

AGC-3' as sense and 5'-CAG GAG GAG CAA TGA TCT TGA T-3' as antisense (Gen Bank accession No. NM_001101.2).

Briefly, 25 *µl* of PCR mixture were prepared using 2.5 *µl* of 10× PCR buffer, 1 *µl* (for *ROR1*) and 3 *µl* (for β-actin) of 25 *mM* MgCl2, 1.5 *µl* dNTPs (10 *mM*), 0.5 *µl* of each primer (10 *pmol/µl*), 0.1 *µl* of Taq-DNA polymerase (5 *U/µl*; CinnaGen, Iran) and 3 *µl* (for *ROR1*) and 1 *µl* (for β-actin) of cDNA. PCR was followed by 37 cycles for *ROR1* and 26 cycles for β-actin. Each cycle of *ROR1* amplification consisted of 92 *°C* for 30 *s*, 62 *°C* for 30 *s*, 72 *°C* for 1 *min* and finally 72 *°C* for 10 *min*. Each cycle of β-actin amplification consisted of 92 *°C* for 30 *s*, 60 *°C* for 30 *s*, 72*°C* for 30 *s* and finally 72 *°C* for 10 *min*. The amplicon sizes of *ROR1* and β-actin PCR products were 545 and 321 *bp*, respectively. PCR products were finally visualized by running agarose gel (1.5%) electrophoresis containing ethidium bromide.

Both *ROR1* and β-actin products of each sample were run simultaneously in a single lane to minimize between-run variations and enhance precision of the assay. After electrophoresis, images were taken using a gel documentation system (UVP, LMS-20E, USA). *ROR1* and β-actin band densities were determined by Labworks 4.0 software (UVP, USA), and the ratio of the two bands was calculated for each sample and multiplied by 100.

Immunophenotyping of leukemic cells

Mononuclear cells from BM or PB of CLL and AML patients were immunophenotyped by flow cytometry using FITC- or PE-conjugated monoclonal antibodies (mAbs), as previously described [19,20]. Staining of at least 20% of the leukemic cells after subtraction of background staining with isotype matched conjugated mAbs of irrelevant specificity was considered positive.

Statistical analysis

Analyses were conducted using the SPSS statistical package (SPSS, Chicago, IL). Statistical analyses of the results were performed using Chi-Square, Fisher's exact tests, and Mann-Whitney U tests as appropriate. P-values of less than 0.05 were considered significant.

Results

Relative expression of *ROR1* mRNA levels in patients and normal subjects was determined by calculation of the ratio of *ROR1* PCR product band density to that of β-actin. The level of expression of *ROR1* mRNA was determined in all samples by visualization of the corresponding PCR product following electrophoresis. Representative RT-PCR results obtained for a number of patients and normal samples are illustrated in figure 1.

Baseline level of *ROR1* expression was assigned as mean + 1SD of *ROR1*/β-actin ratio of 33 normal subjects [17]. Accordingly, 4 of 33 normal samples were found to be positive. Of the 84 CLL samples 79 (94%) were positive (Figure 2). However, no significant differences were observed between indolent (n=42) and progressive (n=39) subtypes. Similarly, no substantial differences were observed between IGHV mutated (n=55) and unmutated (n=29) groups of patients (Figure 3).

Comparison of the expression levels of *ROR1* between CLL and normal subjects demonstrated significantly higher expression levels in CLL patients ($p < 0.0001$) (Figure 2). Contrary to CLL, none of the AML patients was found to express *ROR1* mRNA (Figures 1 and 2). There is no significant difference of



Figure 1. Representative expression profile of *ROR1* mRNA in peripheral blood (PB) or bone marrow (BM) samples of a number of patients and healthy subjects. PCR amplicons of *ROR1* (545 *bp*) and β-actin (321 *bp*) genes were electrophoresed on 1.5% ethidium bromide- stained gel and photographed. Lane 1: size marker; Lanes 2-5: CLL (PB); Lanes 6-9: AML (6 and 8: PB and 7 and 9: BM); Lanes 10-12: healthy subjects (PB)

Downloaded from http://www.ajmb.org



Figure 2. Relative expression levels of *ROR1* mRNA in CLL, ALL and AML patients and normal subjects. The horizontal line denotes the cutoff value obtained from the normal samples; the data of ALL patients has been taken from ref 17. Relative expression of ROR1 mRNA levels in samples was determined by calculation of the ratio of ROR1 PCR product band density to that of β-actin. Baseline level of ROR1 expression was assigned as mean + 1SD of ROR1/ β-actin ratio of normal subjects.
*** : p-values of less than 0.0001
** : p-values of less than 0.005



Figure 3. Representative expression profile of *ROR1* in different subgroups of CLL patients. PCR amplicons of ROR1 (545 *bp*) and β-actin (321 *bp*) genes were electrophoresed on 1.5% ethidium bromide-stained agarose gel and photographed. Lanes 1-4: patients with indolent disease; Lanes 5-7: patients with progressive disease; lane 8: size marker; Lanes 9-11: patients with mutated leukemic cells; Lanes 12-14: patients with unmutated leukemic cells

ROR1 expression between BM and PB samples of our AML patients (data not presented).

Discussion

Lymphoid and myeloid malignancies are a diverse group of neoplasms derived from clonal expansion of lymphocytes and monocytes arrested at different stages of differentiation [22]. Exploration of the immunophenotypes of leukemic cells in relation to the normal hemopoietic differentiation reveals profiles that closely mimic those of corresponding normal cells at equivalent levels of maturation [23]. However, the gene expression profile of the leukemic cells is not the same as that of the normal counterpart and displays many similarities and differences [7,24-27]. Gene expression profile of the leukemic B cells in follicular lymphoma, hairy cell leukemia and CLL has been shown to resemble the germinal center or the memory stage of differentiation [7,24,28,29]. Nevertheless, some genes such as *fibromodulin (FMOD)*, *ROR1* and some members of the *WNT* gene family are selectively overexpressed in the leukemic CLL B cells and are not detected in normal B cells [7,13,24,30,31].

ROR1 has recently been extensively investigated due to its potential biological functions as a member of receptor tyrosine kinase family. Although its counterparts in other species fulfill diverse recognized biological functions, its role in human still remains unknown [32]. In addition, functional *ROR1* ligands have remained unknown, even though Fukuda et al showed *ROR1* could bind Wnt5a [5]. They found that Wnt5a induced activation of NF-κB when coexpressed with *ROR1* in HEK293 cells and enhanced the survival of CLL cells in vitro, an effect that could be neutralized by post-treatment with anti-ROR1 antisera [5]. It has recently been demonstrated that IL-6 activated Stat3 binds to the ROR1 promoter and activates ROR1 in CLL cells [33]. Interestingly, systematic knock down of all known and putative human kinases in the human cervical cancer cell line HeLa by siRNA, has introduced *ROR1* as an inhibitor of apoptosis [34], suggesting its role in etiopathogenesis of the implicated tumors.

This assumption is supported by our results of *ROR1* expression in 94% and 40% of Iranian CLL and ALL patients, respectively (Figure 2 and [17]). The expression level of *ROR1* in our CLL patients was significantly higher than that obtained in our earlier study for the Iranian ALL patients [17] ($p<0.0001$). Compatible with our results Basker et al and Daneshmanesh et al have recently shown *ROR1* expression both at mRNA and protein levels in all Caucasian CLL patients investigated [11,13]. At protein level, Ror1 expression

Downloaded from http://www.ajmb.org

is selectively expressed on the surface of B-CLL cells, whereas normal B cells, other normal blood cells and normal adult tissues do not express cell surface Ror1 [5,11,13]. In addition to CLL *ROR1* is also expressed in non-Hodgkin's lymphomas, with high expression in mantle cell lymphoma and moderate expression in marginal zone lymphoma [15,16], but not in major adult tissues apart from low levels in adipose tissue and at an early stage of B-cell development [15].

Interestingly, *ROR1* mRNA was completely negative in all our AML patients (12/12) (Figure 2). There is only one detailed report on *ROR1* expression in AML, which is in line with our results. Muller-Tidow et al have analyzed expression of all human receptor tyrosine kinases (n=56) in malignant tumors of different origins and normal control samples by quantitative real-time RT-PCR. They showed that the AML samples expressed only 20 different receptor tyrosine kinases, but surprisingly none of their 85 AML patients expressed *ROR1*, with the exception of only one sample with weak expression [35]. No published data is available regarding *ROR1* expression at protein level in AML. It is important to study more cases of AML as well as other myeloid leukemias, such as chronic myeloid leukemia and promyelocytic leukemia from different ethnic origins to prove its lack of association to the myeloid lineage.

Conclusion

In conclusion the present study provides evidence suggesting that expression of *ROR1* might be associated to lineage and differentiation stages of leukemic cells with a potential implication for immunotherapy.

Acknowledgement

We thank Mahin Kordmahin, Tahereh Shahrestani, and Khadijeh Esmailzadeh for their invaluable technical assistance. The authors report no conflicts of interest. This study was supported by grants from Tehran University of Medical Sciences and the Ministry of Health and Medical Education of Iran.

References

1. Masiakowski P, Carroll RD. A novel family of cell surface receptors with tyrosine kinase-like domain. J Biol Chem 1992;267(36):26181-26190.
2. Nomi M, Oishi I, Kani S, Suzuki H, Matsuda T, Yoda A, et al. Loss of mRor1 enhances the heart and skeletal abnormalities in mRor2-deficient mice: redundant and pleiotropic functions of mRor1 and mRor2 receptor tyrosine kinases. Mol Cell Biol 2001;21(24):8329-8335.
3. Wang HY, Liu T, Malbon CC. Structure-function analysis of Frizzleds. Cell Signal 2006;18(7):934-941.
4. Grumolato L, Liu G, Mong P, Mudbhary R, Biswas R, Arroyave R, et al. Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. Genes Dev 2010;24 (22):2517-2530.
5. Fukuda T, Chen L, Endo T, Tang L, Lu D, Castro JE, et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci USA 2008;105 (8):3047-3052.
6. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001;194(11):1625-1638.
7. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194(11):1639-1647.
8. Haiat S, Billard C, Quiney C, Ajchenbaum-Cymbalista F, Kolb JP. Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology 2006;118(3):281-292.
9. Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet 2008;371(9617):1017-1029.
10. Hamblin TJ. Prognostic markers in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2007;20(3):455-68.
11. Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, Lee E, et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res 2008;14(2):396-404.
12. Hojjat-Farsangi M, Jeddi-Tehrani M, Razavi SM, Sharifian RA, Mellstedt H, Shokri F, et al. Immunoglobulin heavy chain variable region gene

Downloaded from http://www.ajmb.org

usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia. Cancer Science 2009;100(12):2346-2353.

13. Daneshmanesh AH, Mikaelsson E, Jeddi-Tehrani M, Bayat AA, Ghods R, Ostadkarampour M, et al. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer 2008;123(5):1190-1195.
14. Rabbani H, Ostadkarampour M, Daneshmanesh AH, Basiri A, Jeddi-Tehrani M, Forouzesh F. Expression of ROR1 in patients with renal cancer-a potential diagnostic marker. Iran Biomed J 2010; 14(3):77-82.
15. Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 2010;116 (22):4532-4541.
16. Barna G, Mihalik R, Timar B, Tombol J, Csende Z, Sebestyen A, et al. ROR1 expression is not a unique marker of CLL. Hematol Oncol 2011;29(1): 17-21.
17. Shabani M, Asgarian-Omran H, Jeddi-Tehrani M, Vossough P, Faranoush M, Sharifian RA, et al. Overexpression of orphan receptor tyrosine kinase Ror1 as a putative tumor-associated antigen in Iranian patients with acute lymphoblastic leukemia. Tumour Biol 2007;28(6):318-326.
18. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94(6):1848-1854.
19. Kazemi T, Asgarian-Omran H, Hojjat-Farsangi M, Shabani M, Memarian A, Sharifian RA, et al. Fc receptor-like 1-5 molecules are similarly expressed in progressive and indolent clinical subtypes of B-cell chronic lymphocytic leukemia. Int J Cancer 2008;123(9):2113-2119.
20. Asgarian Omran H, Shabani M, Shahrestani T, Sarafnejad A, Khoshnoodi J, Vossough P, et al. Over-expression of Wilm's Tumor Gene 1(WT1) in Iranian patients with acute myeloblastic leukemia. Iran J Immunol 2005;2(4):182-190.
21. Farsangi MH, Jeddi-Tehrani M, Sharifian RA, Razavi SM, Khoshnoodi J, Rabbani H, et al. Analysis of the immunoglobulin heavy chain variable region gene expression in Iranian patients with chronic lymphocytic leukemia. Leuk Lymphoma 2007;48 (1):109-116.
22. Greaves MF. Biological models for leukaemia and lymphoma. IARC Sci Publ 2004(157):351-372.
23. Thiel E. Cell surface markers in leukemia: biological and clinical correlations. Crit Rev Oncol Hematol 1985;2(3):209-260.
24. Dunphy CH. Gene expression profiling data in lymphoma and leukemia: review of the literature and extrapolation of pertinent clinical applications. Arch Pathol Lab Med 2006;130(4):483-520.
25. Virtaneva K, Wright FA, Tanner SM, Yuan B, Lemon WJ, Caligiuri MA, et al. Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. Proc Natl Acad Sci USA 2001;98(3):1124-1129.
26. Wang J, Coombes KR, Highsmith WE, Keating MJ, Abruzzo LV. Differences in gene expression between B-cell chronic lymphocytic leukemia and normal B cells: a meta-analysis of three microarray studies. Bioinformatics 2004;20(17):3166-3178.
27. Scrideli CA, Cazzaniga G, Fazio G, Pirola L, Callegaro A, Bassan R, et al. Gene expression profile unravels significant differences between childhood and adult Ph+ acute lymphoblastic leukemia. Leukemia 2003;17(11):2234-2237.
28. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403(6769):503-511.
29. Basso K, Liso A, Tiacci E, Benedetti R, Pulsoni A, Foa R, et al. Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med 2004;199(1):59-68.
30. Mikaelsson E, Daneshmanesh AH, Luppert A, Jeddi-Tehrani M, Rezvany MR, Sharifian RA, et al. Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Blood 2005;105(12): 4828-4835.
31. Memarian A, Hojjat-Farsangi M, Asgarian-Omran H, Younesi V, Jeddi-Tehrani M, Sharifian RA, et al. Variation in WNT genes expression in different subtypes of chronic lymphocytic leukemia. Leuk Lymphoma 2009;50(12):2061-2070.
32. Yoda A, Oishi I, Minami Y. Expression and function of the Ror-family receptor tyrosine kinases during development: lessons from genetic analyses of nematodes, mice, and humans. J Recept Signal Transduct Res 2003;23(1):1-15.

Downloaded from http://www.ajmb.org

33. Li P, Harris D, Liu Z, Liu J, Keating M, Estrov Z. Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells. PloS One 2010;5(7):e11859.

34. MacKeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 2005;7(6):591-600.

35. Muller-Tidow C, Schwable J, Steffen B, Tidow N, Brandt B, Becker K, et al. High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. Clin Cancer Res 2004;10(4):1241-1249.

Downloaded from http://www.ajmb.org